Approaches to the detection of ovarian cancer

被引:8
作者
Hogdall, Estrid [1 ]
机构
[1] Univ Copenhagen, Herlev & Gentofte Univ Hosp, Dept Pathol, Mol Unit, Herlev Ringvej 75, DK-2730 Herlev, Denmark
关键词
CA125; Copenhagen Index; HE4; Risk of Malignancy Index; MALIGNANCY ALGORITHM ROMA; EUROPEAN-GROUP; TUMOR-MARKERS; INDEX; CA125; HE-4; RISK; BIOMARKERS; GUIDELINES; EXPRESSION;
D O I
10.1080/00365513.2016.1208452
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Ovarian cancer (OC) represents the eighth most common cancer among women and the second most frequently diagnosed gynecological malignancy in the United States and Europe. Correct and fast referral of patients with OC is mandatory to ensure optimal treatment and to improve the prognosis of patients with OC. Approaches to detect OC may be based on a gynecological examination, an elevated serum CA125 level, a Risk of Malignancy Index (RMI) higher than 200, an elevated serum HE4 level, or other modalities such as Risk of Ovarian Malignancy Algorithm (ROMA), Risk of Ovarian Cancer Algorithm (ROCA), or Copenhagen Index (CPH-I).Aim: To describe biomarkers that potentially improve the detection/risk estimation of OC.Results: The ability to differentiate OC from benign and borderline ovarian tumors was analyzed using Receiver Operating Characteristics (ROC) curves resulting in Area Under the Curve (AUC) of 0.920 for CA125, 0.933 for HE4 and 0.946 for ROMA. The ROC curves of OC versus benign ovarian tumors shows that the CPH-I (AUC=0.959) is equivalent with RMI (AUC=0.958).Conclusion: Both ROMA and CPH-I could potentially shorten the time spent before OC patients reach a tertiary center thereby improve risk estimation/diagnosis. Biomarker research still has to be performed in relevant clinical settings before any overall decisions can be made with respect to screening.
引用
收藏
页码:S49 / S53
页数:5
相关论文
共 25 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]  
*DGCG, 2016, RETN VIS DIAGN KONTR
[3]   CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use [J].
Duffy, MJ ;
Bonfrer, JM ;
Kulpa, J ;
Rustin, GJS ;
Soletormos, G ;
Torre, GC ;
Tuxen, MK ;
Zwirner, M .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :679-691
[4]  
Engholm G., 2015, NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries
[5]   Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey [J].
Fago-Olsen, Carsten L. ;
Hogdall, Claus ;
Kehlet, Henrik ;
Christensen, Ib J. ;
Ottesen, Bent .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2011, 90 (03) :273-279
[6]   Who should operate on patients with ovarian cancer? An evidence-based review [J].
Giede, KC ;
Kieser, K ;
Dodge, J ;
Rosen, B .
GYNECOLOGIC ONCOLOGY, 2005, 99 (02) :447-461
[7]   Time intervals from first symptom to treatment of cancer: a cohort study of 2,212 newly diagnosed cancer patients [J].
Hansen, Rikke P. ;
Vedsted, Peter ;
Sokolowski, Ineta ;
Sondergaard, Jens ;
Olesen, Frede .
BMC HEALTH SERVICES RESEARCH, 2011, 11
[8]  
Hellström I, 2003, CANCER RES, V63, P3695
[9]   THE ROLE OF SERUM TETRANECTIN, CA-125, AND A COMBINED INDEX AS TUMOR-MARKERS IN WOMEN WITH PELVIC TUMORS [J].
HOGDALL, CK ;
MOGENSEN, O ;
TABOR, A ;
MOGENSEN, B ;
JAKOBSEN, AKM ;
NORGAARDPEDERSEN, B ;
LARSEN, SO ;
CLEMMENSEN, I .
GYNECOLOGIC ONCOLOGY, 1995, 56 (01) :22-28
[10]  
JACOBS I, 1988, BIOMED PHARMACOTHER, V42, P589